A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
BeOne Medicines
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Nurix Therapeutics, Inc.
Verismo Therapeutics
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
AbbVie
Calibr, a division of Scripps Research
Hackensack Meridian Health
Massachusetts General Hospital
Dana-Farber Cancer Institute
AbbVie
Ohio State University Comprehensive Cancer Center
Acerta Pharma BV
Nurix Therapeutics, Inc.
Cellectar Biosciences, Inc.
Rigshospitalet, Denmark
Beth Israel Deaconess Medical Center
M.D. Anderson Cancer Center
University of Chicago
Seoul National University Hospital
Gilead Sciences
University of Washington
Mayo Clinic
BeOne Medicines
Eli Lilly and Company
ModeX Therapeutics, An OPKO Health Company
Mayo Clinic
Fundación Española de Hematología y Hemoterapía
Dana-Farber Cancer Institute
Ascentage Pharma Group Inc.
Mayo Clinic
Newave Pharmaceutical Inc
Schrödinger, Inc.
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
City of Hope Medical Center
BeOne Medicines
iOMEDICO AG
Eli Lilly and Company
Fondazione Italiana Linfomi - ETS
BeOne Medicines